Hikma Pharmaceuticals
PLC
(the
Company)
Total Voting Rights and
Capital
LONDON, 1 July 2024 - In accordance
with section 5.6.1 of the UK Financial Conduct Authority's
Disclosure Guidance and Transparency Rules
(the 'Rules'), Hikma Pharmaceuticals PLC notifies the market of the
following:
As at 30 June 2024,
the issued share capital of the Company
comprised of 221,886,453
Ordinary Shares of 10
pence each ('Shares') with voting rights. This figure excludes 12,833,233 Shares held in treasury, which
do not have voting rights.
The figure of 221,886,453 may be used by
shareholders (and others with notification obligations) as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the Company under the Rules.
- ENDS -
Enquiries
|
Hikma Pharmaceuticals PLC
|
|
|
Helen Middlemist
Group Company Secretary
|
+44 20
7399 2760
|
About Hikma
Hikma helps put better health within
reach every day for millions of people around the world. For more
than 45 years, we've been creating high-quality medicines and
making them accessible to the people who need them. Headquartered
in the UK, we are a global company with a local presence across
North America, the Middle East and North Africa (MENA) and Europe,
and we use our unique insight and expertise to transform
cutting-edge science into innovative solutions that transform
people's lives. We're committed to our customers, and the people
they care for, and by thinking creatively and acting practically,
we provide them with a broad range of branded and non-branded
generic medicines. Together, our 9,100 colleagues are helping to
shape a healthier world that enriches all our communities. We are a
leading licensing partner, and through our venture capital arm, are
helping bring innovative health technologies to people around the
world. For more information, please visit:
www.hikma.com
Hikma Pharmaceuticals PLC (LSE: HIK)
(NASDAQ Dubai: HIK) (OTC: HKMPY)
(LEI:
549300BNS685UXH4JI75)